Taken together, our study identifies a novel link between NCALD and adult neurogenesis in the hippocampus, possibly via MAP3K10-JNK pathway and establishes the safety of NCALD reduction as viable option for a combinatorial therapy to treat SMA. The gene discussed is MAP3K10; the disease is proximal spinal muscular atrophy.